SARS-CoV-2 nsp13 Helicase (E. co

Confirm delete?

SARS-CoV-2 nsp13 Helicase (E. coli expressed)

Zoom

Cat No: 30589

Proteins - More Proteins

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus and the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

NSP 13 Escherichia corona virus nonstructural 1 B PP1 a PP ORF Rec 2 IFN? RIGI 293 FT

Product Overview:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus and the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.{53462,53459,53461,55257,55258} The SARS-CoV-2 genome contains approximately 30 kilobases and 14 open reading frames (ORFs) that encode four structural proteins: spike, envelope, membrane, and nucleocapsid, as well as 16 non-structural proteins and 9 accessory factors.{57176} SARS-CoV-2 nsp13 helicase is a superfamily 1B helicase and component of replicase polyprotein 1a (PP1a), which is encoded by ORF1a in the viral genome. It is composed of two canonical RecA-like ATPase domains, 1A and 2A, and a zinc-binding domain, stalk region, and 1B domain.{57175,57181} SARS-CoV-2 nsp13 functions as both an RNA helicase and a nucleoside triphosphate hydrolase (NTPase), unwinding RNA in an NTP-dependent manner.{57177} It inhibits IFN-β reporter gene activation induced by the RIG-I 2CARD domain in 293FT cells, indicating a role for nsp13 helicase in suppression of the host immune response.{57182} Cayman's SARS-CoV-2 nsp13 Helicase (E. coli expressed) protein can be used for enzyme assays and Western blot (WB) applications.

Size	10 µg
Shipping	dry ice
Formulation	50 mM Tris-HCl, pH 7.5, with 5 µM zinc chloride, 1 mM DTT, 1 mM EDTA, and 15% glycerol
Purity	≥70% estimated by SDS-PAGE
Custom Code	3507.90
UNSPSC code	12352204

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.